MIMETAS Raises 5.2 Million Dollar For Organ-on-a-Chip

Venture capital investors Zeeuws Investerings Fonds and Participatiemaatschapij Oost Nederland have joined forces with national and regional partners to fund development and sales of MIMETAS’ unique 3D disease- and tissue modelling technologies.

Jos Joore, co-founder and Chief Business Officer of MIMETAS, acknowledges that these resources arrive at a strategically important moment: “Collaborations with top-tier pharmaceutical companies are expanding rapidly, an example of this is the recently announced 1.6 million dollar kidney-on-a-chip project with Roche, Pfizer and GlaxoSmithKline. The funds will be used to scale up the production of OrganoPlates™ and strengthen our activities in predictive preclinical model development, thus consolidating our leadership in this highly competitive field.”

Currently, MIMETAS has a range of disease-, toxicology- and ADME models in her pipeline, in various stages of development and validation.

“We immediately recognised MIMETAS’ large upside potential”, says Johan Sebregts, managing director of ZIF, “To help developing this, we support MIMETAS not only with capital, but also through the vast expertise of our shareholders that include Dutch captains of industry”. 

Marius Prins, CEO of PPM Oost, who is also very pleased with the investment in MIMETAS, states: “Significant value creation through better disease models with reduced laboratory animal use is highly relevant to our fund. In addition, this strategic investment helps us to pair two top technology clusters in the Netherlands in one thriving enterprise: biotechnology at the Leiden Bioscience Park and microfluidics at Twente University.”